Association between CCND1 G870A polymorphism and radiotherapy response in high-risk human papillomavirus-related cervical cancer.
10.11817/j.issn.1672-7347.2015.11.007
- Author:
Shaoqiang LIANG
1
;
Ning ZHANG
2
;
Rong HUANG
2
;
Jun JIANG
2
;
Lusi CHEN
2
;
Zhiqian LU
2
;
Shaoen LI
2
Author Information
1. Department of Radiotherapy, Tumor Hosipital of the First People's Hospital of Foshan, Foshan Guangdong 528000, China lsqwenzhang@aliyun.com.
2. Department of Radiotherapy, Tumor Hosipital of the First People's Hospital of Foshan, Foshan Guangdong 528000, China.
- Publication Type:Journal Article
- MeSH:
Cyclin D1;
genetics;
Female;
Genotype;
Humans;
Papillomaviridae;
Polymorphism, Single Nucleotide;
Prognosis;
Uterine Cervical Neoplasms;
genetics;
radiotherapy;
virology
- From:
Journal of Central South University(Medical Sciences)
2015;40(11):1205-1209
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the correlation of cyclin D1 (CCND1) G870A single nucleotide polymorphism (SNP) with radiotherapy response in patients with high risk human papillomavirus (HR-HPV) related cervical cancer.
METHODS:A total of 273 patients with cervical cancer, who were confirmed by histopathology and hybrid capture 2 (HC-2) assay and treated by radiotherapy, were enrolled for this study. The correlation of CCND1 G870A polymorphism with tumor response in patients was assessed.
RESULTS:Compared with patients with AA genotype, the patients with GG genotype and AA genotype showed lower sensitivity to radio-therapy treatment (adjusted ORGA=2.69, 95% CI 1.28-5.67 and adjusted ORGG=3.28, 95% CI 1.47-7.29, respectively), an increase in risks of recurrence/metastasis (adjusted ORGA=2.52, 95% CI 1.12-5.63 and adjusted ORGG=3.95, 95% CI 1.68-9.26, respectively), and shorter recurrence/metastasis-free survival (PGA=0.010 and PGG=0.045).
CONCLUSION:G870A polymorphism is a frequent variation that could be used for evaluate the radio-sensitivity and prognosis for patients with HR-HPV related cervical cancer.
